Usage of Orange Peel Extract in Management of Epistaxis
The Potential of Nano-based Gel of Orange Peel Extract in Management of Epistaxis : a Randomized Double Blind Clinical Study
1 other identifier
interventional
60
0 countries
N/A
Brief Summary
Efficacy of orange peel extract in treatment of epistaxis in children
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2025
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2025
CompletedFirst Submitted
Initial submission to the registry
February 15, 2025
CompletedFirst Posted
Study publicly available on registry
February 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedFebruary 20, 2025
February 1, 2025
2 months
February 15, 2025
February 15, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
The potential of nano-based gel of Orange peel extract in management of epistaxis
assessment of epistaxis ( amount, severity and frequency ) according to ESS ( Epistaxis Severity Score ) between patients in study groups
From enrollment to the end of treatment at 4 weeks
Study Arms (3)
gel of Orange peel extract
ACTIVE COMPARATORusage of gel of Orange peel extract as a local treatment of epistaxis
nano-based gel of Orange peel extract
ACTIVE COMPARATORusage of nano-based gel of Orange peel extract as a local treatment of epistaxis
placebo
PLACEBO COMPARATORusage of placebo in control cases
Interventions
usage of orange peel extract in gel layer in treatment of epistaxis
Eligibility Criteria
You may qualify if:
- children with anterior epistaxis from little's area
You may not qualify if:
- patient with nasal polyp.
- patients with hematological abnormalities.
- patients with general diseases affecting coagulation system.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Minia Universitylead
Related Publications (1)
Andrade MA, Barbosa CH, Shah MA, Ahmad N, Vilarinho F, Khwaldia K, Silva AS, Ramos F. Citrus By-Products: Valuable Source of Bioactive Compounds for Food Applications. Antioxidants (Basel). 2022 Dec 25;12(1):38. doi: 10.3390/antiox12010038.
PMID: 36670900BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- lecturer of otorhinolaryngology Minia university
Study Record Dates
First Submitted
February 15, 2025
First Posted
February 20, 2025
Study Start
February 1, 2025
Primary Completion
April 1, 2025
Study Completion
May 1, 2025
Last Updated
February 20, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- ICF, CSR
- Time Frame
- 3 months
- Access Criteria
- contact by emailing
result